secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001171843-23-006818
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q3 net loss $6.0M, cash $32.2M; soquelitinib Phase 3 trial protocol finalized
--------------------------------------------------------------------------------

- Net loss $6.0M vs $14.8M in Q3 2022; R&D expenses down to $4.0M from $10.4M.
- Cash, equivalents and marketable securities $32.2M as of Sept 30, 2023 (Dec 31, 2022: $42.3M).
- ATM program raised $7.8M net from 2.46M shares; FY 2023 cash burn guidance $22-23M.
- Soquelitinib Phase 3 registrational trial for relapsed PTCL protocol finalized; enrollment expected Q2 2024; Phase 2 in RCC planned early 2024.
- New soquelitinib data accepted for ASH Dec 2023; preclinical autoimmune/allergy data published.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323006818/0001171843-23-006818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323006818/f8k_110723.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer